The researchers used a novel method called thermal proteome profiling to detect cellular changes induced
by palbociclib.
Not exact matches
«While it was known that
palbociclib stalls proliferation
by inhibiting CDK4 / 6, inducing proteasomal activity may be an additional mechanism that ensures the completeness of the cell cycle arrest,» says Dr. Mikael Björklund, one of the lead authors of the study.
The breast cancer drug
palbociclib arrests cells in G1 phase
by CDK4 / 6 inhibition, but also causes cellular senescence.
The proteasome is a novel downstream target for the anti ‐ cancer drug
palbociclib inhibiting proliferation
by reduced proteasomal association with its inhibitor EMC29.
Thermal proteome profiling of breast cancer cells reveals proteasomal activation
by CDK4 / 6 inhibitor
palbociclib, The EMBO Journal (2018).
However, recent observations indicate that
palbociclib induces a more complete arrest than what can be achieved
by blocking CDK4 / 6.